| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $7,499,991 | 1 | 100 |
Sells | $0 | 0 | 0 |
| PERCEPTIVE ADVISORS LLC | director | 1 | $7.5M | 0 | $0 | $7.5M |
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or …
Over the last 12 months, insiders at Immatics N.V. have bought $7.5M and sold $0 worth of Immatics N.V. stock.
On average, over the past 5 years, insiders at Immatics N.V. have bought $7.5M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (director) — $7.5M.
The last purchase of 863,060 shares for transaction amount of $7.5M was made by PERCEPTIVE ADVISORS LLC (director) on 2026‑08‑26.
| 2026-08-26 | PERCEPTIVE ADVISORS LLC | director | 863,060 0.5931% | $8.69 | $7.5M | -11.45% |
| Increased Positions | 47 | +71.21% | 19M | +20.71% |
| Decreased Positions | 29 | -43.94% | 10M | -10.83% |
| New Positions | 19 | New | 4M | New |
| Sold Out Positions | 8 | Sold Out | 6M | Sold Out |
| Total Postitions | 84 | +27.27% | 102M | +9.88% |